Nova Eye Medical (EYE) Discussion, page-2449

It really depends on when the market notices this, which is why it's so important for the company to get out there and spread the word. Already with current fundamentals it should be valued at a significantly higher market cap based on a peer analysis. You've got a high growth and soon to be profitable med tech company with a massive R&D pipeline valued at a multiple of only 2x revenue, which is quite insane. Lower growth peers usually fetch revenue multiples above 5, and often above 10 as well.

So considering we've seen them steadily maintain the high growth rate in the US, and that they've confirmed near term profitability, I'm sure the market will eventually notice this one and rerate it hard. It's really more a question of when that happens, you can't really predict whether it'll happen this week or next month or next year. 2RT could also be a complete game changer, once that comes more into the picture it has the potential to be so massive that we could simply forget about iTrack Advance. That's exciting but also makes it a little difficult to predict the outlook, as there are certainly plenty of opportunities here for the company beyond simply continuing to grow revenue and profits for iTrack Advance